Quell Therapeutics Initiates Phase 1/2 Trial for QEL-005 in Autoimmune Diseases
Quell Therapeutics is conducting Phase 1/2 trial of QEL-005, an autologous CAR-T therapy targeting CD19, in patients with dcSSc and D2TRA.
Asset / Drug
Drug and asset intelligence for QEL-005 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.